Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 10/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 5/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344824 | 0.89 | CYP3A4 (0.48) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL3028054 | 0.89 | CYP3A4 (0.50) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL1344317 | 0.89 | KCNH2 (0.47) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL1342651 | 0.88 | CYP3A4 (0.48) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL3037532 | 0.88 | CYP3A4 (0.56) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL27862294 | 0.87 | CYP3A4 (0.47) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL3016459 | 0.86 | CYP3A4 (0.46) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL3028092 | 0.86 | CYP3A4 (0.43) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL3034600 | 0.86 | CYP3A4 (0.43) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL3034388 | 0.86 | CYP3A4 (0.52) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-7947709-B2 | Inhibit HIV-1 RT; 3-[6-Bromo-2-fluoro-3-(2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-phenoxy]-5-chloro-benzonitrile for example; AIDS or AIDS-related Complex (ARC) | ROCHE PALO ALTO LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2170836-A1 | UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090012034-A1 | Non-Nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2009-01-08 | — | — | US | disclosed |
| WO-2009000663-A1 | UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | CYP3A4 169/4885KCNH2 4114/4885CYP2C9 720/4885 |
| US-20090012034-A1 | Non-Nucleoside reverse transcriptase inhibitors | REV1, POLR1A, XDH | CYP3A4 1026/4885KCNH2 4014/4885CYP2C9 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.